Eton Pharmaceuticals Inc., of Deer Park, Ill., will collaborate with Aucta Pharmaceuticals Inc., of Piscataway, N.J., to acquire U.S. marketing rights for ET-105, a patent-pending formulation of lamotrigine to be delivered to patients as an oral liquid.